This is a Scorecard review, revisiting a past LF0 research call against what actually happened.
Ticker: AEHR Rating: Sell Published: 2026-06-18 Checkpoint: 2026-07-18 Entry price: $115.30 Latest price: $81.05 as of 2026-07-17 Stock return since entry: -29.7% Signal return: +29.7% Verdict: Correct so far
This is the 1-month checkpoint for this call. LF0 publishes monthly Scorecard updates through month 6, using the closest available daily close on or before the checkpoint date.
Read the original LF0 analysis
What I Said
I argued that AEHR’s product differentiation and cash position were not enough to offset the core operating picture: revenue was still falling sharply year over year, margins were deeply negative, and cash flow was burning. My view was that the valuation left too little room for error unless the company could show sustained improvement in revenue, EBITDA, and cash generation.
Peer Comparison
| Company | Return Since Entry |
|---|---|
| AEHR (this call) | -29.7% |
| ACLS | -37.6% |
| AMAT | -25.4% |
| FORM | -32.3% |
| KLAC | -32.1% |
| ONTO | -18.8% |
Why It’s Working (Or Not)
So far, a short position would have worked: AEHR is down about 29.7% since my entry, which means the bearish signal has been rewarded. The peer group has also been weak overall, with most of the comparable names posting negative returns over the same window, so AEHR’s move has happened in a generally soft semiconductor-equipment backdrop rather than in isolation. That said, the key part of my thesis that has been validated is the idea that the stock had little margin for execution error; the market has continued to punish the name while the trailing fundamentals I highlighted remain the central concern. I still cannot claim the business has turned around, only that the price action has so far moved in the direction my Sell call anticipated.
What Could Still Prove Me Wrong
I would be wrong if AEHR starts showing the sustained operating improvement I said was missing: revenue stabilizing and then growing, EBITDA moving meaningfully toward breakeven, and cash burn easing rather than continuing. If the company can demonstrate that the negative-margin, cash-consuming profile is improving faster than the market expected, the valuation argument behind my Sell call would weaken. A durable rebound in the stock alongside those fundamentals would be the clearest evidence that my thesis no longer holds.
The June 2026 Cohort
Other directional calls published the same month:
| Ticker | Rating | Entry | Latest | Stock Return | Signal Return | Verdict |
|---|---|---|---|---|---|---|
| SKYH | Sell | $9.37 | $10.52 | +12.3% | -12.3% | Incorrect so far |
| BSX | Buy | $46.76 | $46.67 | -0.2% | -0.2% | Incorrect so far |
| SOUN | Sell | $7.33 | $7.22 | -1.5% | +1.5% | Correct so far |
| CAR | Sell | $186.28 | $139.49 | -25.1% | +25.1% | Correct so far |
| BW | Sell | $17.76 | $7.68 | -56.8% | +56.8% | Correct so far |
Live LF0 scorecard: The Scorecard | Research Performance dashboard
Past performance does not guarantee future results. Nothing here is investment advice or a recommendation to buy or sell securities. Returns use LF0’s daily-close scorecard methodology.
Leave a Comment